These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15027499)

  • 1. Planning analyses of quality-of-life studies: a case example with migraine prophylaxis.
    Fairclough DL; Gagnon D; Papadopoulos G
    J Biopharm Stat; 2004 Feb; 14(1):31-51. PubMed ID: 15027499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate for migraine prevention.
    Wenzel RG; Schwarz K; Padiyara RS
    Pharmacotherapy; 2006 Mar; 26(3):375-87. PubMed ID: 16503717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The analysis, interpretation, and presentation of quality of life data.
    Stephens R
    J Biopharm Stat; 2004 Feb; 14(1):53-71. PubMed ID: 15027500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
    Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
    Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of topiramate on health-related quality of life indicators in chronic migraine.
    Dodick DW; Silberstein S; Saper J; Freitag FG; Cady RK; Rapoport AM; Mathew NT; Hulihan J; Crivera C; Rupnow MF; Mao L; Finlayson G; Greenberg SJ
    Headache; 2007; 47(10):1398-408. PubMed ID: 18052949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
    Brown JS; Papadopoulos G; Neumann PJ; Friedman M; Miller JD; Menzin J
    Headache; 2005 Sep; 45(8):1012-22. PubMed ID: 16109115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate improves health-related quality of life when used to prevent migraine.
    Diamond M; Dahlöf C; Papadopoulos G; Neto W; Wu SC
    Headache; 2005 Sep; 45(8):1023-30. PubMed ID: 16109116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate for migraine prophylaxis.
    Drug Ther Bull; 2006 Aug; 44(8):62-4. PubMed ID: 16903488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
    Eickhoff JC
    Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multilevel latent variable models for global health-related quality of life assessment.
    Kifley A; Heller GZ; Beath KJ; Bulger D; Ma J; Gebski V
    Stat Med; 2012 May; 31(11-12):1249-64. PubMed ID: 22302410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate.
    Silberstein S; Diener HC; Lipton R; Goadsby P; Dodick D; Bussone G; Freitag F; Schwalen S; Ascher S; Morein J; Greenberg S; Biondi D; Hulihan J
    Headache; 2008 Jul; 48(7):1087-95. PubMed ID: 18687081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate (topamax) for prevention of migraine.
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1136-7. PubMed ID: 15863557
    [No Abstract]   [Full Text] [Related]  

  • 13. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis comparing topiramate with standard treatments in migraine prophylaxis.
    Ergun H; Gulmez SE; Tulunay FC
    Eur Neurol; 2007; 58(4):215-7. PubMed ID: 17827966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Move over LOCF: principled methods for handling missing data in sleep disorder trials.
    Olsen MK; Stechuchak KM; Edinger JD; Ulmer CS; Woolson RF
    Sleep Med; 2012 Feb; 13(2):123-32. PubMed ID: 22172964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which health-related quality-of-life outcome when planning randomized trials: disease-specific or generic, or both? A common factor model.
    Ades AE; Lu G; Madan JJ
    Value Health; 2013; 16(1):185-94. PubMed ID: 23337230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern mixture models for longitudinal quality of life studies in advanced stage disease.
    Pauler DK; McCoy S; Moinpour C
    Stat Med; 2003 Mar; 22(5):795-809. PubMed ID: 12587106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.
    Bussone G; Diener HC; Pfeil J; Schwalen S
    Int J Clin Pract; 2005 Aug; 59(8):961-8. PubMed ID: 16033621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study.
    Bussone G; Usai S; D'Amico D
    Neurol Sci; 2006 May; 27 Suppl 2():S159-63. PubMed ID: 16688622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.